- Conditions
- Solid Tumours
- Interventions
- AZD4956, Saruparib
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 4
- States / cities
- New York, New York • Providence, Rhode Island • Houston, Texas + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2185–2208
of 21,991
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Ultomiris-exposed Pregnant/ Postpartum, Pregnancy, Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS), Generalized Myasthenia Gravis (gMG), Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Interventions
- Ultomiris
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- Female only
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2034
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma, Recurrent Adenoid Cystic Carcinoma
- Interventions
- CB-103, Abemaciclib, Lenvatinib
- Drug
- Lead sponsor
- Michael J. Dennis, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Breast Cancer, Gastrointestinal Cancer, Hematologic Cancer
- Interventions
- OPTIMISE
- Behavioral
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 340 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Aortic Stenosis
- Interventions
- Impedance Cardiography Upright/Supine Test
- Device
- Lead sponsor
- Dermed Diagnostics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Smoking Cessation
- Interventions
- HealthyCells
- Behavioral
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Advanced Solid Tumor, Unresectable Solid Tumor, Metastatic Solid Tumor, Cholangiocarcinoma
- Interventions
- Afatinib, Pemigatinib
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Bronchiectasis, Cystic Fibrosis, Autoimmune Disease, Common Variable Immunodeficiency
- Interventions
- Not listed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 5 Years to 100 Years
- Enrollment
- 900 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2009
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Amyloid Plaque, Beta-Amyloid, DSAD, Prodromal Alzheimer's Disease, Alzheimer's Disease
- Interventions
- Placebo (Study Part 1a), ACI-24.060 at Dose A in Study Part 1a, ACI-24.060 at Dose B in Study Part 1a, ACI-24.060 at Dose C in Study Part 1a, ACI-24.060 with an additional adjuvant at Dose D in Study Part 1b, Placebo (Study Part 2), ACI-24.060 at Dose A in Study Part 2, ACI-24.060 at Dose B in Study Part 2, ACI-24.060 at Dose C in Study Part 2, Placebo (Study Part 1b), ACI-24.060 with an additional adjuvant at Dose E in Study Part 1b
- Biological
- Lead sponsor
- AC Immune SA
- Industry
- Eligibility
- 35 Years to 85 Years
- Enrollment
- 304 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Lady Lake, Florida • Orlando, Florida + 9 more
- Conditions
- Mucopolysaccharidosis IV Type A, Morquio A Syndrome, MPS IVA
- Interventions
- Imaging, gait analysis, growth, joint test, hearing test, questionnaire, etc.
- Diagnostic Test
- Lead sponsor
- Nemours Children's Clinic
- Other
- Eligibility
- Not listed
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Wilmington, Delaware
- Conditions
- Contraception
- Interventions
- Ovaprene
- Device
- Lead sponsor
- Daré Bioscience, Inc.
- Industry
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 656 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 24 more
- Conditions
- Neoplasm, Colorectal, Cognitive Impairment, Cognitive Dysfunction, Cognitive Change, Chemo-brain, Chemo Fog, Chemotherapy Effect, Cognitive Decline
- Interventions
- Not listed
- Lead sponsor
- Joseph McCollom
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2031
- U.S. locations
- 1
- States / cities
- Fort Wayne, Indiana
- Conditions
- Borderline Personality Disorder
- Interventions
- MDMA
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Post Traumatic Stress Disorder, Cardiovascular Diseases, Autonomic Dysfunction, Vascular Stiffness, Nightmare, Endothelial Dysfunction, Kidney Diseases, Renal Dysfunction, Trauma and Stressor Related Disorders
- Interventions
- NightWare, Sham NightWare
- Device
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 22 Years to 40 Years · Female only
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Denver, Colorado
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Positive Breast Carcinoma, Oligometastatic Breast Carcinoma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Breast Conservation Treatment, Computed Tomography, Cyclin-Dependent Kinase 4 Inhibitor, Cyclin-Dependent Kinase 6 Inhibitor, Echocardiography Test, HER2-targeted Therapy, Hormone Therapy, Magnetic Resonance Imaging, Mammography, Pertuzumab, Positron Emission Tomography, Radiation Boost, Radiation Therapy, Stereotactic Body Radiation Therapy, Stereotactic Radiosurgery, Taxane Compound, Total Mastectomy, Trastuzumab, Trastuzumab Deruxtecan, Trastuzumab Emtansine, Ultrasound Imaging
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 562 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2033
- U.S. locations
- 59
- States / cities
- Jonesboro, Arkansas • Derby, Connecticut • Fairfield, Connecticut + 45 more
- Conditions
- Cardiomyopathy, Hypertrophic Obstructive
- Interventions
- BHB-1893, Metoprolol
- Drug
- Lead sponsor
- Braveheart Bio, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 3
- States / cities
- Manhasset, New York • Rock Hill, South Carolina • Plano, Texas
- Conditions
- Obesity, Adolescent, Healthy Nutrition, Sedentary Behavior, Drug Abuse
- Interventions
- Wakaya: Rising Up for Choctaw Youth Curriculum
- Behavioral
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 12 Years to 19 Years
- Enrollment
- 176 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 2
- States / cities
- Durant, Oklahoma • Seattle, Washington
- Conditions
- Gaucher Disease
- Interventions
- no intervention
- Other
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 30 participants
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Healthy
- Interventions
- LY4302814, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Daytona Beach, Florida
- Conditions
- Sickle Cell Disease
- Interventions
- Daratumumab, Alemtuzumab, Sirolimus, Total Body Irradiation
- Drug · Radiation
- Lead sponsor
- Children's National Research Institute
- Other
- Eligibility
- 2 Years to 25 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2054
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Recurrent Adult T-Cell Leukemia/Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Adult T-Cell Leukemia/Lymphoma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
- Interventions
- Cyclophosphamide, Fludarabine, Mogamulizumab, Natural Killer Cell Therapy, Quality-of-Life Assessment, Questionnaire Administration
- Drug · Biological · Other
- Lead sponsor
- John Reneau
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Arrythmia, Cardiomyopathies
- Interventions
- Intra-Op Prophylactic VT ablation, Conventional Management
- Procedure · Other
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Francisco, California + 15 more
- Conditions
- Hemophilia B
- Interventions
- CSL222 (AAV5-hFIXco-Padua)
- Genetic
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 4
- States / cities
- San Diego, California • Ann Arbor, Michigan • Pittsburgh, Pennsylvania + 1 more
- Conditions
- Military Sexual Trauma, Intimate Partner Violence, Brain Injury, Post Traumatic Stress Disorder
- Interventions
- webSTAIR, ExpoTx, PsychoEd
- Behavioral · Other
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas